Share Price and Basic Stock Data
Last Updated: January 13, 2026, 8:28 pm
| PEG Ratio | 2.91 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Abbott India Ltd, a prominent player in the pharmaceuticals sector, reported a current price of ₹28,485 and a market capitalization of ₹60,531 Cr. The company has shown consistent revenue growth, with trailing twelve-month (TTM) sales standing at ₹6,714 Cr, reflecting a steady increase from ₹5,349 Cr in FY 2023. This growth trajectory is underscored by quarterly sales figures, which rose from ₹1,379 Cr in September 2022 to ₹1,494 Cr in September 2023, demonstrating a robust demand for its products. The company’s operational efficiency is also notable, with an operating profit margin (OPM) of 29% as of the latest reporting period. This is significantly higher than the typical sector average, indicating strong pricing power and cost management strategies. The sales growth is complemented by a diversified product portfolio, which includes essential medications and nutritional products, positioning Abbott India favorably within the competitive landscape of the pharmaceutical industry.
Profitability and Efficiency Metrics
Abbott India reported a net profit of ₹1,509 Cr, reflecting a net profit margin of 22.06% for FY 2025, which is above the sector average. The company’s return on equity (ROE) stood at an impressive 35.7%, showcasing its ability to generate substantial returns for shareholders. The return on capital employed (ROCE) was even more remarkable at 46.2%, indicating efficient use of capital to drive profitability. The interest coverage ratio (ICR) of 172.37x further illustrates Abbott’s strong financial health, suggesting that the company comfortably manages its interest obligations. The cash conversion cycle (CCC) of just 3 days indicates exceptional operational efficiency in managing receivables and inventory. These metrics collectively signify a well-managed organization that not only thrives in profitability but also maintains a strong operational framework, which is crucial in the capital-intensive pharmaceutical sector.
Balance Sheet Strength and Financial Ratios
Abbott India’s balance sheet reflects a solid financial foundation, with total reserves amounting to ₹3,990 Cr against borrowings of only ₹182 Cr. This low level of debt underscores the company’s conservative approach to leverage, enhancing its financial stability. The book value per share, including revaluation reserves, was reported at ₹1,992.07 for FY 2025, indicating substantial equity backing per share. The price-to-book value ratio stood at 15.43x, which, while high, suggests strong market confidence in the company’s future growth prospects. Moreover, the current ratio of 3.39x indicates a strong liquidity position, well above the typical threshold of 1.5x for the sector, ensuring that Abbott can meet its short-term obligations comfortably. The efficient management of assets is further highlighted by a return on assets (ROA) of 23.90%, demonstrating the effectiveness of its asset utilization in generating profits.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Abbott India indicates a strong commitment from its promoters, who hold 74.99% of the equity. This high level of promoter ownership often correlates with aligned interests between management and shareholders, fostering confidence in the company’s strategic direction. Foreign institutional investors (FIIs) have a marginal stake of 0.16%, while domestic institutional investors (DIIs) hold 9.11%, reflecting cautious interest from institutional players. The public holding stands at 15.74%, with a total of 71,199 shareholders as of the latest reporting period. The relatively low foreign investment suggests potential for growth in this area, as increased FII participation could enhance stock liquidity and market perception. The stable shareholding structure, combined with strong financial metrics, positions Abbott India favorably among investors, although the low FII presence may signal a need for enhanced investor relations efforts to attract foreign capital.
Outlook, Risks, and Final Insight
Looking ahead, Abbott India is well-positioned to capitalize on its strong operational performance and financial health, but it faces certain risks. The pharmaceutical sector is subject to stringent regulatory scrutiny, which can impact product approvals and market entry timelines. Additionally, rising raw material costs and competitive pressures could affect profit margins if not managed effectively. On the other hand, Abbott’s robust R&D capabilities and diverse product offerings provide a buffer against market volatility. The company’s ability to innovate and adapt to changing consumer needs will be crucial for sustaining growth. In scenarios where operational efficiencies continue to improve and regulatory environments remain favorable, Abbott could potentially enhance its market share and profitability further. Conversely, any adverse regulatory changes or significant market disruptions could pose challenges to its growth trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 132 Cr. | 104 | 208/84.3 | 29.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,008 Cr. | 367 | 479/192 | 83.0 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.5 Cr. | 47.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 57.9 Cr. | 39.5 | 41.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,214.20 Cr | 1,122.62 | 52.34 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,379 | 1,322 | 1,343 | 1,479 | 1,494 | 1,437 | 1,439 | 1,558 | 1,633 | 1,614 | 1,605 | 1,738 | 1,757 |
| Expenses | 1,036 | 1,010 | 1,063 | 1,124 | 1,113 | 1,049 | 1,109 | 1,167 | 1,194 | 1,178 | 1,176 | 1,293 | 1,255 |
| Operating Profit | 343 | 312 | 280 | 355 | 381 | 388 | 330 | 391 | 439 | 436 | 429 | 446 | 502 |
| OPM % | 25% | 24% | 21% | 24% | 25% | 27% | 23% | 25% | 27% | 27% | 27% | 26% | 29% |
| Other Income | 34 | 44 | 50 | 56 | 56 | 56 | 81 | 67 | 60 | 72 | 76 | 73 | 70 |
| Interest | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 4 | 6 | 8 |
| Depreciation | 17 | 18 | 17 | 17 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 19 | 19 |
| Profit before tax | 355 | 335 | 308 | 390 | 415 | 422 | 390 | 437 | 479 | 488 | 483 | 493 | 546 |
| Tax % | 25% | 26% | 25% | 26% | 25% | 26% | 26% | 25% | 25% | 26% | 24% | 26% | 24% |
| Net Profit | 266 | 247 | 231 | 290 | 313 | 311 | 287 | 328 | 359 | 361 | 367 | 366 | 415 |
| EPS in Rs | 124.95 | 116.16 | 108.91 | 136.59 | 147.27 | 146.35 | 135.09 | 154.36 | 168.76 | 169.78 | 172.73 | 172.18 | 195.43 |
Last Updated: December 28, 2025, 10:34 am
Below is a detailed analysis of the quarterly data for Abbott India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1,757.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,738.00 Cr. (Jun 2025) to 1,757.00 Cr., marking an increase of 19.00 Cr..
- For Expenses, as of Sep 2025, the value is 1,255.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,293.00 Cr. (Jun 2025) to 1,255.00 Cr., marking a decrease of 38.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 502.00 Cr.. The value appears strong and on an upward trend. It has increased from 446.00 Cr. (Jun 2025) to 502.00 Cr., marking an increase of 56.00 Cr..
- For OPM %, as of Sep 2025, the value is 29.00%. The value appears strong and on an upward trend. It has increased from 26.00% (Jun 2025) to 29.00%, marking an increase of 3.00%.
- For Other Income, as of Sep 2025, the value is 70.00 Cr.. The value appears to be declining and may need further review. It has decreased from 73.00 Cr. (Jun 2025) to 70.00 Cr., marking a decrease of 3.00 Cr..
- For Interest, as of Sep 2025, the value is 8.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.00 Cr. (Jun 2025) to 8.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Sep 2025, the value is 19.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 19.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 546.00 Cr.. The value appears strong and on an upward trend. It has increased from 493.00 Cr. (Jun 2025) to 546.00 Cr., marking an increase of 53.00 Cr..
- For Tax %, as of Sep 2025, the value is 24.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Jun 2025) to 24.00%, marking a decrease of 2.00%.
- For Net Profit, as of Sep 2025, the value is 415.00 Cr.. The value appears strong and on an upward trend. It has increased from 366.00 Cr. (Jun 2025) to 415.00 Cr., marking an increase of 49.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 195.43. The value appears strong and on an upward trend. It has increased from 172.18 (Jun 2025) to 195.43, marking an increase of 23.25.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:20 am
| Metric | Mar 2014n n 15m | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,276 | 2,289 | 2,614 | 2,903 | 3,298 | 3,679 | 4,093 | 4,310 | 4,919 | 5,349 | 5,849 | 6,409 | 6,714 |
| Expenses | 2,009 | 1,977 | 2,250 | 2,505 | 2,774 | 3,074 | 3,336 | 3,388 | 3,832 | 4,143 | 4,396 | 4,714 | 4,902 |
| Operating Profit | 267 | 312 | 365 | 398 | 525 | 605 | 757 | 922 | 1,088 | 1,206 | 1,453 | 1,695 | 1,812 |
| OPM % | 12% | 14% | 14% | 14% | 16% | 16% | 18% | 21% | 22% | 23% | 25% | 26% | 27% |
| Other Income | 49 | 48 | 50 | 57 | 117 | 113 | 114 | 81 | 77 | 154 | 248 | 275 | 291 |
| Interest | 0 | 0 | 3 | 2 | 4 | 2 | 9 | 18 | 19 | 16 | 12 | 11 | 20 |
| Depreciation | 22 | 15 | 14 | 16 | 16 | 17 | 60 | 58 | 66 | 70 | 71 | 72 | 74 |
| Profit before tax | 295 | 344 | 398 | 436 | 621 | 699 | 803 | 926 | 1,080 | 1,274 | 1,618 | 1,887 | 2,009 |
| Tax % | 33% | 34% | 36% | 37% | 35% | 36% | 26% | 25% | 26% | 25% | 26% | 25% | |
| Net Profit | 198 | 229 | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,414 | 1,509 |
| EPS in Rs | 93.39 | 107.75 | 120.12 | 130.19 | 188.82 | 211.93 | 279.04 | 325.04 | 375.87 | 446.80 | 565.30 | 665.64 | 710.12 |
| Dividend Payout % | 25% | 29% | 29% | 31% | 29% | 31% | 90% | 85% | 73% | 73% | 73% | 71% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 11.35% | 8.63% | 44.77% | 12.22% | 31.78% | 16.53% | 15.63% | 18.77% | 26.55% | 17.74% |
| Change in YoY Net Profit Growth (%) | 0.00% | -2.73% | 36.14% | -32.55% | 19.56% | -15.25% | -0.90% | 3.14% | 7.78% | -8.82% |
Abbott India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 9% |
| 3 Years: | 9% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 19% |
| 3 Years: | 21% |
| TTM: | 17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 14% |
| 3 Years: | 21% |
| 1 Year: | 8% |
| Return on Equity | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 32% |
| 3 Years: | 34% |
| Last Year: | 36% |
Last Updated: September 5, 2025, 2:01 pm
Balance Sheet
Last Updated: December 4, 2025, 2:16 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 767 | 916 | 1,174 | 1,366 | 1,672 | 1,987 | 2,410 | 2,581 | 2,799 | 3,167 | 3,678 | 4,212 | 3,990 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 175 | 153 | 152 | 113 | 83 | 197 | 182 |
| Other Liabilities | 351 | 436 | 421 | 679 | 723 | 932 | 940 | 1,086 | 1,253 | 1,254 | 1,411 | 1,487 | 1,501 |
| Total Liabilities | 1,139 | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 | 5,694 |
| Fixed Assets | 98 | 96 | 108 | 110 | 81 | 105 | 270 | 251 | 271 | 237 | 225 | 336 | 314 |
| CWIP | 1 | 4 | 3 | 6 | 2 | 1 | 2 | 1 | 1 | 4 | 10 | 18 | 23 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,040 | 1,274 | 1,505 | 1,950 | 2,333 | 2,835 | 3,275 | 3,589 | 3,952 | 4,315 | 4,958 | 5,563 | 5,357 |
| Total Assets | 1,139 | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 | 5,694 |
Below is a detailed analysis of the balance sheet data for Abbott India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,990.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,212.00 Cr. (Mar 2025) to 3,990.00 Cr., marking a decrease of 222.00 Cr..
- For Borrowings, as of Sep 2025, the value is 182.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 197.00 Cr. (Mar 2025) to 182.00 Cr., marking a decrease of 15.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,501.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,487.00 Cr. (Mar 2025) to 1,501.00 Cr., marking an increase of 14.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 5,694.00 Cr.. The value appears to be improving (decreasing). It has decreased from 5,917.00 Cr. (Mar 2025) to 5,694.00 Cr., marking a decrease of 223.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 314.00 Cr.. The value appears to be declining and may need further review. It has decreased from 336.00 Cr. (Mar 2025) to 314.00 Cr., marking a decrease of 22.00 Cr..
- For CWIP, as of Sep 2025, the value is 23.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Mar 2025) to 23.00 Cr., marking an increase of 5.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 5,357.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,563.00 Cr. (Mar 2025) to 5,357.00 Cr., marking a decrease of 206.00 Cr..
- For Total Assets, as of Sep 2025, the value is 5,694.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,917.00 Cr. (Mar 2025) to 5,694.00 Cr., marking a decrease of 223.00 Cr..
Notably, the Reserves (3,990.00 Cr.) exceed the Borrowings (182.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014n n 15m | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 267.00 | 312.00 | 365.00 | 398.00 | 525.00 | 605.00 | 582.00 | 769.00 | -151.00 | -112.00 | -82.00 | -196.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 18 | 21 | 20 | 22 | 29 | 27 | 28 | 21 | 21 | 22 | 20 | 22 |
| Inventory Days | 101 | 107 | 91 | 107 | 112 | 106 | 83 | 110 | 94 | 80 | 70 | 92 |
| Days Payable | 38 | 54 | 56 | 101 | 92 | 116 | 104 | 116 | 122 | 109 | 114 | 110 |
| Cash Conversion Cycle | 80 | 74 | 54 | 28 | 49 | 17 | 8 | 14 | -6 | -8 | -24 | 3 |
| Working Capital Days | 36 | 30 | 32 | 21 | 63 | 22 | 10 | 7 | -7 | -8 | -14 | 97 |
| ROCE % | 39% | 40% | 38% | 34% | 41% | 37% | 35% | 35% | 38% | 41% | 46% | 46% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Large & Midcap Fund | 274,878 | 2.23 | 826.7 | 155,000 | 2025-10-30 02:04:49 | 77.34% |
| Axis Midcap Fund | 165,040 | 1.54 | 496.36 | 166,043 | 2025-12-15 00:53:44 | -0.6% |
| Canara Robeco Large and Mid Cap Fund | 144,836 | 1.66 | 435.59 | N/A | N/A | N/A |
| Nippon India Multi Cap Fund | 87,483 | 0.53 | 263.11 | 44,742 | 2025-10-30 04:11:08 | 95.53% |
| SBI MNC Fund | 80,000 | 4.01 | 240.6 | N/A | N/A | N/A |
| PGIM India Midcap Fund | 74,300 | 1.94 | 223.46 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 68,677 | 2.44 | 206.55 | 76,390 | 2025-10-30 04:11:08 | -10.1% |
| Franklin India Mid Cap Fund | 52,304 | 1.22 | 157.3 | N/A | N/A | N/A |
| SBI Healthcare Opportunities Fund | 40,000 | 2.91 | 120.3 | N/A | N/A | N/A |
| Canara Robeco Flexi Cap Fund | 32,022 | 0.69 | 96.31 | 42,310 | 2025-10-30 04:11:08 | -24.32% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 665.62 | 565.28 | 446.78 | 375.86 | 325.04 |
| Diluted EPS (Rs.) | 665.62 | 565.28 | 446.78 | 375.86 | 325.04 |
| Cash EPS (Rs.) | 699.41 | 598.77 | 479.71 | 406.96 | 352.38 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1992.07 | 1740.65 | 1500.49 | 1326.96 | 1224.55 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1992.07 | 1740.65 | 1500.49 | 1326.96 | 1224.55 |
| Dividend / Share (Rs.) | 475.00 | 410.00 | 325.00 | 275.00 | 275.00 |
| Revenue From Operations / Share (Rs.) | 3016.07 | 2752.43 | 2517.05 | 2314.95 | 2028.24 |
| PBDIT / Share (Rs.) | 927.14 | 800.64 | 639.90 | 548.20 | 471.70 |
| PBIT / Share (Rs.) | 893.36 | 767.15 | 606.97 | 517.10 | 444.34 |
| PBT / Share (Rs.) | 887.98 | 761.29 | 599.44 | 508.11 | 435.74 |
| Net Profit / Share (Rs.) | 665.62 | 565.28 | 446.78 | 375.86 | 325.03 |
| PBDIT Margin (%) | 30.74 | 29.08 | 25.42 | 23.68 | 23.25 |
| PBIT Margin (%) | 29.61 | 27.87 | 24.11 | 22.33 | 21.90 |
| PBT Margin (%) | 29.44 | 27.65 | 23.81 | 21.94 | 21.48 |
| Net Profit Margin (%) | 22.06 | 20.53 | 17.75 | 16.23 | 16.02 |
| Return on Networth / Equity (%) | 33.41 | 32.47 | 29.77 | 28.32 | 26.54 |
| Return on Capital Employeed (%) | 42.09 | 42.33 | 38.50 | 36.37 | 33.60 |
| Return On Assets (%) | 23.90 | 23.12 | 20.84 | 18.90 | 17.98 |
| Asset Turnover Ratio (%) | 1.15 | 1.20 | 1.22 | 1.22 | 1.17 |
| Current Ratio (X) | 3.39 | 2.42 | 2.51 | 3.20 | 3.41 |
| Quick Ratio (X) | 2.76 | 1.96 | 1.97 | 2.63 | 2.72 |
| Inventory Turnover Ratio (X) | 8.54 | 9.22 | 0.83 | 0.70 | 0.72 |
| Dividend Payout Ratio (NP) (%) | 61.59 | 57.49 | 61.54 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 58.61 | 54.27 | 57.32 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 38.41 | 42.51 | 38.46 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 41.39 | 45.73 | 42.68 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 172.37 | 136.66 | 85.04 | 60.99 | 54.83 |
| Interest Coverage Ratio (Post Tax) (X) | 124.75 | 97.48 | 60.38 | 42.82 | 38.78 |
| Enterprise Value (Cr.) | 63674.71 | 55125.76 | 44996.86 | 34862.11 | 29441.84 |
| EV / Net Operating Revenue (X) | 9.93 | 9.42 | 8.41 | 7.09 | 6.83 |
| EV / EBITDA (X) | 32.32 | 32.40 | 33.09 | 29.93 | 29.37 |
| MarketCap / Net Operating Revenue (X) | 10.19 | 9.79 | 8.77 | 7.65 | 7.39 |
| Retention Ratios (%) | 38.40 | 42.50 | 38.45 | 0.00 | 0.00 |
| Price / BV (X) | 15.43 | 15.48 | 14.72 | 13.34 | 12.24 |
| Price / Net Operating Revenue (X) | 10.19 | 9.79 | 8.77 | 7.65 | 7.39 |
| EarningsYield | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
After reviewing the key financial ratios for Abbott India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 665.62. This value is within the healthy range. It has increased from 565.28 (Mar 24) to 665.62, marking an increase of 100.34.
- For Diluted EPS (Rs.), as of Mar 25, the value is 665.62. This value is within the healthy range. It has increased from 565.28 (Mar 24) to 665.62, marking an increase of 100.34.
- For Cash EPS (Rs.), as of Mar 25, the value is 699.41. This value is within the healthy range. It has increased from 598.77 (Mar 24) to 699.41, marking an increase of 100.64.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,992.07. It has increased from 1,740.65 (Mar 24) to 1,992.07, marking an increase of 251.42.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,992.07. It has increased from 1,740.65 (Mar 24) to 1,992.07, marking an increase of 251.42.
- For Dividend / Share (Rs.), as of Mar 25, the value is 475.00. This value exceeds the healthy maximum of 3. It has increased from 410.00 (Mar 24) to 475.00, marking an increase of 65.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 3,016.07. It has increased from 2,752.43 (Mar 24) to 3,016.07, marking an increase of 263.64.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 927.14. This value is within the healthy range. It has increased from 800.64 (Mar 24) to 927.14, marking an increase of 126.50.
- For PBIT / Share (Rs.), as of Mar 25, the value is 893.36. This value is within the healthy range. It has increased from 767.15 (Mar 24) to 893.36, marking an increase of 126.21.
- For PBT / Share (Rs.), as of Mar 25, the value is 887.98. This value is within the healthy range. It has increased from 761.29 (Mar 24) to 887.98, marking an increase of 126.69.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 665.62. This value is within the healthy range. It has increased from 565.28 (Mar 24) to 665.62, marking an increase of 100.34.
- For PBDIT Margin (%), as of Mar 25, the value is 30.74. This value is within the healthy range. It has increased from 29.08 (Mar 24) to 30.74, marking an increase of 1.66.
- For PBIT Margin (%), as of Mar 25, the value is 29.61. This value exceeds the healthy maximum of 20. It has increased from 27.87 (Mar 24) to 29.61, marking an increase of 1.74.
- For PBT Margin (%), as of Mar 25, the value is 29.44. This value is within the healthy range. It has increased from 27.65 (Mar 24) to 29.44, marking an increase of 1.79.
- For Net Profit Margin (%), as of Mar 25, the value is 22.06. This value exceeds the healthy maximum of 10. It has increased from 20.53 (Mar 24) to 22.06, marking an increase of 1.53.
- For Return on Networth / Equity (%), as of Mar 25, the value is 33.41. This value is within the healthy range. It has increased from 32.47 (Mar 24) to 33.41, marking an increase of 0.94.
- For Return on Capital Employeed (%), as of Mar 25, the value is 42.09. This value is within the healthy range. It has decreased from 42.33 (Mar 24) to 42.09, marking a decrease of 0.24.
- For Return On Assets (%), as of Mar 25, the value is 23.90. This value is within the healthy range. It has increased from 23.12 (Mar 24) to 23.90, marking an increase of 0.78.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.15. It has decreased from 1.20 (Mar 24) to 1.15, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 3.39. This value exceeds the healthy maximum of 3. It has increased from 2.42 (Mar 24) to 3.39, marking an increase of 0.97.
- For Quick Ratio (X), as of Mar 25, the value is 2.76. This value exceeds the healthy maximum of 2. It has increased from 1.96 (Mar 24) to 2.76, marking an increase of 0.80.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.54. This value exceeds the healthy maximum of 8. It has decreased from 9.22 (Mar 24) to 8.54, marking a decrease of 0.68.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 61.59. This value exceeds the healthy maximum of 50. It has increased from 57.49 (Mar 24) to 61.59, marking an increase of 4.10.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 58.61. This value exceeds the healthy maximum of 50. It has increased from 54.27 (Mar 24) to 58.61, marking an increase of 4.34.
- For Earning Retention Ratio (%), as of Mar 25, the value is 38.41. This value is below the healthy minimum of 40. It has decreased from 42.51 (Mar 24) to 38.41, marking a decrease of 4.10.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 41.39. This value is within the healthy range. It has decreased from 45.73 (Mar 24) to 41.39, marking a decrease of 4.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 172.37. This value is within the healthy range. It has increased from 136.66 (Mar 24) to 172.37, marking an increase of 35.71.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 124.75. This value is within the healthy range. It has increased from 97.48 (Mar 24) to 124.75, marking an increase of 27.27.
- For Enterprise Value (Cr.), as of Mar 25, the value is 63,674.71. It has increased from 55,125.76 (Mar 24) to 63,674.71, marking an increase of 8,548.95.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.93. This value exceeds the healthy maximum of 3. It has increased from 9.42 (Mar 24) to 9.93, marking an increase of 0.51.
- For EV / EBITDA (X), as of Mar 25, the value is 32.32. This value exceeds the healthy maximum of 15. It has decreased from 32.40 (Mar 24) to 32.32, marking a decrease of 0.08.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 10.19. This value exceeds the healthy maximum of 3. It has increased from 9.79 (Mar 24) to 10.19, marking an increase of 0.40.
- For Retention Ratios (%), as of Mar 25, the value is 38.40. This value is within the healthy range. It has decreased from 42.50 (Mar 24) to 38.40, marking a decrease of 4.10.
- For Price / BV (X), as of Mar 25, the value is 15.43. This value exceeds the healthy maximum of 3. It has decreased from 15.48 (Mar 24) to 15.43, marking a decrease of 0.05.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 10.19. This value exceeds the healthy maximum of 3. It has increased from 9.79 (Mar 24) to 10.19, marking an increase of 0.40.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Abbott India Ltd:
- Net Profit Margin: 22.06%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 42.09% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 33.41% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 124.75
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.76
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 39.5 (Industry average Stock P/E: 52.34)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 22.06%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 3, Corporate Park, Mumbai Maharashtra 400071 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Munir Shaikh | Chairman |
| Mr. Kartik Rajendran | Managing Director |
| Mr. Kaiyomarz Marfatia | Non Executive Director |
| Mr. Ambati Venu | Non Executive Director |
| Ms. Alison Davies | Non Executive Director |
| Ms. Anisha Motwani | Independent Director |
| Ms. Shalini Kamath | Independent Director |
| Mr. Sudarshan Jain | Independent Director |
FAQ
What is the intrinsic value of Abbott India Ltd?
Abbott India Ltd's intrinsic value (as of 13 January 2026) is ₹21658.86 which is 22.89% lower the current market price of ₹28,090.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹59,620 Cr. market cap, FY2025-2026 high/low of ₹37,000/25,260, reserves of ₹3,990 Cr, and liabilities of ₹5,694 Cr.
What is the Market Cap of Abbott India Ltd?
The Market Cap of Abbott India Ltd is 59,620 Cr..
What is the current Stock Price of Abbott India Ltd as on 13 January 2026?
The current stock price of Abbott India Ltd as on 13 January 2026 is ₹28,090.
What is the High / Low of Abbott India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Abbott India Ltd stocks is ₹37,000/25,260.
What is the Stock P/E of Abbott India Ltd?
The Stock P/E of Abbott India Ltd is 39.5.
What is the Book Value of Abbott India Ltd?
The Book Value of Abbott India Ltd is 1,888.
What is the Dividend Yield of Abbott India Ltd?
The Dividend Yield of Abbott India Ltd is 1.69 %.
What is the ROCE of Abbott India Ltd?
The ROCE of Abbott India Ltd is 46.2 %.
What is the ROE of Abbott India Ltd?
The ROE of Abbott India Ltd is 35.7 %.
What is the Face Value of Abbott India Ltd?
The Face Value of Abbott India Ltd is 10.0.